GSK Sees Blockbuster Chronic Cough Opportunity With $2bn Bellus Buyout
Potential Best-In-Class Drug
Executive Summary
GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.
You may also be interested in...
How To Be An Early-Stage Biotech CEO In Challenging Times
The ongoing downturn is making early-stage biotech leaders work harder to gain funding – but new technology, business focus and better working practices could help them achieve success.
Vaccines Helped GSK Post Strong Q1 Results Ahead Of RSV Approval
Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’
Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.